PBYI— PUMA BIOTECHNOLOGY, INC.

MaterialsBiotechnology$442M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Total revenue	$228.4M-0.9%	$230.5M-2.2%	$235.6M+3.3%	$228.0M
Cost of sales	$58.2M-9.7%	$64.4M+2.7%	$62.7M+13.8%	$55.1M
Selling, general and administrative	$70.8M-11.6%	$80.2M-10.9%	$89.9M-0.1%	$90.0M
Research and development	$62.1M+13.0%	$54.9M+9.0%	$50.4M-3.6%	$52.2M
Total operating costs and expenses	$191.1M-4.2%	$199.5M-1.7%	$203.0M-0.6%	$204.3M
Income from operations	$37.3M+20.5%	$31.0M-5.1%	$32.6M+37.6%	$23.7M
Interest income	$4.1M-13.7%	$4.7M+81.3%	$2.6M+220.4%	$813K
Interest expense	-$6.6M+46.8%	-$12.5M+6.6%	-$13.3M-15.0%	-$11.6M
Other income	$1.0M+19.1%	$862K+13.6%	$759K+2810.7%	-$28K
Total other expenses, net	-$1.5M+77.9%	-$6.9M+31.1%	-$10.0M+57.2%	-$23.3M
Income Before Income Taxes	$35.8M+48.5%	$24.1M+6.3%	$22.7M+4861.5%	$457K
Current income tax (expense)	-$1.4M-59.0%	-$897K	—	—
Deferred income tax (expense) benefit	-$3.2M-145.9%	$7.1M	—	—
Net income	$31.1M+2.8%	$30.3M+40.2%	$21.6M+1079450.0%	$2K
Net income per share of common stock—basic (in dollars per share)	$0.62+0.0%	$0.62+34.8%	$0.46	$0.00
Net income per share of common stock—diluted (in dollars per share)	$0.61-1.6%	$0.62+37.8%	$0.45	$0.00
Weighted-average shares of common stock outstanding—basic (in shares)	50.0M+2.8%	48.6M+3.2%	47.1M+5.5%	44.7M
Weighted-average shares of common stock outstanding—diluted (in shares)	50.7M+3.2%	49.1M+3.3%	47.6M+5.8%	44.9M
Product [Member]
Royalty [Member]

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.